Engineered extracellular vesicles efficiently deliver CRISPR-Cas9 ribonucleoprotein (RNP) to inhibit herpes simplex virus1 infection in vitro and in vivo
Extracellular vesicles (EVs) have recently emerged as a promising delivery platform for CRISPR/Cas9 ribonucleoproteins (RNPs), owing to their ability to minimize off-target effects and immune responses. However, enhancements are required to boost the efficiency and safety of Cas9 RNP enrichment with...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-03-01
|
| Series: | Acta Pharmaceutica Sinica B |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2211383523003878 |
| _version_ | 1797271399539146752 |
|---|---|
| author | Yuanda Wan Liren Li Ruilin Chen Jiajia Han Qiyun Lei Zhipeng Chen Xiaodong Tang Wenyu Wu Shuwen Liu Xingang Yao |
| author_facet | Yuanda Wan Liren Li Ruilin Chen Jiajia Han Qiyun Lei Zhipeng Chen Xiaodong Tang Wenyu Wu Shuwen Liu Xingang Yao |
| author_sort | Yuanda Wan |
| collection | DOAJ |
| description | Extracellular vesicles (EVs) have recently emerged as a promising delivery platform for CRISPR/Cas9 ribonucleoproteins (RNPs), owing to their ability to minimize off-target effects and immune responses. However, enhancements are required to boost the efficiency and safety of Cas9 RNP enrichment within EVs. In response, we employed the Fc/Spa interaction system, in which the human Fc domain was fused to the intracellular domain of PTGFRN-Δ687 and anchored to the EV membrane. Simultaneously, the B domain of the Spa protein was fused to the C domain of cargos such as Cre or spCas9. Due to the robust interaction between Fc and Spa, this method enriched nearly twice the amount of cargo within the EVs. EVs loaded with spCas9 RNP targeting the HSV1 genome exhibited significant inhibition of viral replication in vitro and in vivo. Moreover, following neuron-targeting peptide RVG modification, the in vivo dosage in neural tissues substantially increased, contributing to the clearance of the HSV1 virus in neural tissues and exhibiting a lower off-target efficiency. These findings establish a robust platform for efficient EV-based SpCas9 delivery, offering potential therapeutic advantages for HSV1 infections and other neurological disorders. |
| first_indexed | 2024-03-07T14:02:10Z |
| format | Article |
| id | doaj.art-85431f5a293d4deb8a987de7fa52e85b |
| institution | Directory Open Access Journal |
| issn | 2211-3835 |
| language | English |
| last_indexed | 2024-03-07T14:02:10Z |
| publishDate | 2024-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Acta Pharmaceutica Sinica B |
| spelling | doaj.art-85431f5a293d4deb8a987de7fa52e85b2024-03-07T05:27:30ZengElsevierActa Pharmaceutica Sinica B2211-38352024-03-0114313621379Engineered extracellular vesicles efficiently deliver CRISPR-Cas9 ribonucleoprotein (RNP) to inhibit herpes simplex virus1 infection in vitro and in vivoYuanda Wan0Liren Li1Ruilin Chen2Jiajia Han3Qiyun Lei4Zhipeng Chen5Xiaodong Tang6Wenyu Wu7Shuwen Liu8Xingang Yao9NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, ChinaNMPA Key Laboratory for Research and Evaluation of Drug Metabolism, Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China; Center of Clinical Pharmacy, Nanfang Hospital, Southern Medical University, Guangzhou 510515, ChinaNMPA Key Laboratory for Research and Evaluation of Drug Metabolism, Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, ChinaNMPA Key Laboratory for Research and Evaluation of Drug Metabolism, Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, ChinaNMPA Key Laboratory for Research and Evaluation of Drug Metabolism, Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, ChinaNMPA Key Laboratory for Research and Evaluation of Drug Metabolism, Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, ChinaNMPA Key Laboratory for Research and Evaluation of Drug Metabolism, Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, ChinaState Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou 510060, ChinaNMPA Key Laboratory for Research and Evaluation of Drug Metabolism, Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China; Key Laboratory of Infectious Diseases Research in South China (Southern Medical University), Ministry of Education, Guangzhou 510515, China; Corresponding authors.NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China; Key Laboratory of Infectious Diseases Research in South China (Southern Medical University), Ministry of Education, Guangzhou 510515, China; Corresponding authors.Extracellular vesicles (EVs) have recently emerged as a promising delivery platform for CRISPR/Cas9 ribonucleoproteins (RNPs), owing to their ability to minimize off-target effects and immune responses. However, enhancements are required to boost the efficiency and safety of Cas9 RNP enrichment within EVs. In response, we employed the Fc/Spa interaction system, in which the human Fc domain was fused to the intracellular domain of PTGFRN-Δ687 and anchored to the EV membrane. Simultaneously, the B domain of the Spa protein was fused to the C domain of cargos such as Cre or spCas9. Due to the robust interaction between Fc and Spa, this method enriched nearly twice the amount of cargo within the EVs. EVs loaded with spCas9 RNP targeting the HSV1 genome exhibited significant inhibition of viral replication in vitro and in vivo. Moreover, following neuron-targeting peptide RVG modification, the in vivo dosage in neural tissues substantially increased, contributing to the clearance of the HSV1 virus in neural tissues and exhibiting a lower off-target efficiency. These findings establish a robust platform for efficient EV-based SpCas9 delivery, offering potential therapeutic advantages for HSV1 infections and other neurological disorders.http://www.sciencedirect.com/science/article/pii/S2211383523003878Extracellular vesiclesCRISPR/Cas9RibonucleoproteinsPTGFRNFc/SpaHSV1 |
| spellingShingle | Yuanda Wan Liren Li Ruilin Chen Jiajia Han Qiyun Lei Zhipeng Chen Xiaodong Tang Wenyu Wu Shuwen Liu Xingang Yao Engineered extracellular vesicles efficiently deliver CRISPR-Cas9 ribonucleoprotein (RNP) to inhibit herpes simplex virus1 infection in vitro and in vivo Acta Pharmaceutica Sinica B Extracellular vesicles CRISPR/Cas9 Ribonucleoproteins PTGFRN Fc/Spa HSV1 |
| title | Engineered extracellular vesicles efficiently deliver CRISPR-Cas9 ribonucleoprotein (RNP) to inhibit herpes simplex virus1 infection in vitro and in vivo |
| title_full | Engineered extracellular vesicles efficiently deliver CRISPR-Cas9 ribonucleoprotein (RNP) to inhibit herpes simplex virus1 infection in vitro and in vivo |
| title_fullStr | Engineered extracellular vesicles efficiently deliver CRISPR-Cas9 ribonucleoprotein (RNP) to inhibit herpes simplex virus1 infection in vitro and in vivo |
| title_full_unstemmed | Engineered extracellular vesicles efficiently deliver CRISPR-Cas9 ribonucleoprotein (RNP) to inhibit herpes simplex virus1 infection in vitro and in vivo |
| title_short | Engineered extracellular vesicles efficiently deliver CRISPR-Cas9 ribonucleoprotein (RNP) to inhibit herpes simplex virus1 infection in vitro and in vivo |
| title_sort | engineered extracellular vesicles efficiently deliver crispr cas9 ribonucleoprotein rnp to inhibit herpes simplex virus1 infection in vitro and in vivo |
| topic | Extracellular vesicles CRISPR/Cas9 Ribonucleoproteins PTGFRN Fc/Spa HSV1 |
| url | http://www.sciencedirect.com/science/article/pii/S2211383523003878 |
| work_keys_str_mv | AT yuandawan engineeredextracellularvesiclesefficientlydelivercrisprcas9ribonucleoproteinrnptoinhibitherpessimplexvirus1infectioninvitroandinvivo AT lirenli engineeredextracellularvesiclesefficientlydelivercrisprcas9ribonucleoproteinrnptoinhibitherpessimplexvirus1infectioninvitroandinvivo AT ruilinchen engineeredextracellularvesiclesefficientlydelivercrisprcas9ribonucleoproteinrnptoinhibitherpessimplexvirus1infectioninvitroandinvivo AT jiajiahan engineeredextracellularvesiclesefficientlydelivercrisprcas9ribonucleoproteinrnptoinhibitherpessimplexvirus1infectioninvitroandinvivo AT qiyunlei engineeredextracellularvesiclesefficientlydelivercrisprcas9ribonucleoproteinrnptoinhibitherpessimplexvirus1infectioninvitroandinvivo AT zhipengchen engineeredextracellularvesiclesefficientlydelivercrisprcas9ribonucleoproteinrnptoinhibitherpessimplexvirus1infectioninvitroandinvivo AT xiaodongtang engineeredextracellularvesiclesefficientlydelivercrisprcas9ribonucleoproteinrnptoinhibitherpessimplexvirus1infectioninvitroandinvivo AT wenyuwu engineeredextracellularvesiclesefficientlydelivercrisprcas9ribonucleoproteinrnptoinhibitherpessimplexvirus1infectioninvitroandinvivo AT shuwenliu engineeredextracellularvesiclesefficientlydelivercrisprcas9ribonucleoproteinrnptoinhibitherpessimplexvirus1infectioninvitroandinvivo AT xingangyao engineeredextracellularvesiclesefficientlydelivercrisprcas9ribonucleoproteinrnptoinhibitherpessimplexvirus1infectioninvitroandinvivo |